Licensing Opportunity:
Fermentation process for industrial production of plasmid DNA (pDNA).
NTC’s leading DNA fermentation process technology is being made available for production of DNA vaccines, gene medicines, and plasmids for viral vector production. A standard, non-exclusive commercial license gives access to the patent pending process and proprietary media needed to obtain much higher yields of DNA (up to 1.5g DNA/liter, or more) than are attainable with other available methods.
Advantages
The process results in the bulk of the DNA being pDNA, with only a minor fraction being bacterial (genomic) DNA. This makes the DNA easier to purify from biomass (reduced cell mass per g DNA), dramatically reducing the cost per unit. The DNA is also of higher purity than DNA obtained by comparable methods, and is usually almost 100% covalently closed super-coiled monomer DNA. The cost of production is dramatically reduced because the bulk volume being processed is concomitantly reduced. The process is more environmentally friendly because the waste streams are reduced. The result is the highest possible ROI.
Licensing Mechanism
A non-exclusive commercial license is available for the intended area of use and territory. Generally, a pilot project (Process Development) is used to determine the optimal fermentation conditions, media, etc. for obtaining the highest possible yield from a given plasmid. Based upon production milestones being met, Technology Transfer (of the patent rights, formulae, know-how, etc.) is an available option for GMP facilities and in-house biopharmaceutical production facilities. Expenses associated with acquisition of the technology are largely deferred until late stage clinical trials or FDA licensure, after which industry standard royalties apply.
Licensing Agreement Options
A. )Fermentation Process License Agreement: DNA Manufacturing for Resale
B.) Fermentation Process Commercial Use License Agreement
|
